Scientific Article
previous document  unige:29839  next document
add to browser collection

Biologic therapies for psoriasis. A systematic review

Prinz, Joerg C.
Gottlieb, Alice B.
Published in Journal of Rheumatology. 2006, vol. 33, no. 7, p. 1447-1451
Abstract Alefacept, efalizumab, etanercept, and infliximab are currently approved for the treatment of adults with moderate to severe plaque psoriasis, and phase 3 trials for adalimumab are ongoing. The high level of evidence from large randomized, double-blind, placebo-controlled clinical studies for each of these biologics allows high-grade recommendations and helps define uncertainties, one of which is longterm safety. For tumor necrosis factor-a blocking agents, safety profiles are available from clinical experience in other indications. In general, biologics are safe and effective in the treatment of psoriasis, with potential to address unmet medical needs. Their distinct profiles allow dermatologists to match the biologic agent to individual characteristics of patients who are candidates for systemic therapy or phototherapy. In this evidence-based review of the literature, we assess the effects on psoriasis of induction therapy with 5 biologics and provide preliminary treatment guidelines.
Keywords Antibodies, Monoclonal/*therapeutic useAntibodies, Monoclonal, HumanizedBiological Agents/*therapeutic useClinical Trials as TopicHumansImmunoglobulin G/therapeutic useImmunologic Factors/*therapeutic usePsoriasis/immunology/*therapyReceptors, Tumor Necrosis Factor/therapeutic useRecombinant Fusion Proteins/*therapeutic useTreatment Outcome
PMID: 16724367
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version:
(ISO format)
BOEHNCKE, Wolf-Henning, PRINZ, Joerg C., GOTTLIEB, Alice B. Biologic therapies for psoriasis. A systematic review. In: Journal of Rheumatology, 2006, vol. 33, n° 7, p. 1447-1451.

256 hits

0 download


Deposited on : 2013-09-20

Export document
Format :
Citation style :